Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SK China is the China holding and investment arm of South Korea's SK Group rather than a dedicated biotech or pharmaceutical operating company. In China, it serves as a regional platform for SK's localization, investment, business development, and coordination across multiple sectors. Public descriptions of SK China emphasize investment activity in AI, semiconductors, ICT, new materials, and logistics, while SK Group more broadly also has interests in life sciences through separate affiliates such as SK Biopharmaceuticals and SK pharmteco. Based on available information, SK China itself is best characterized as a diversified regional holding and investment entity, not a standalone life sciences developer with its own disclosed therapeutic pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SK China Holding.